ReviewDigestive diseases and sciences2023

Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates.

David Y GrahamPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.